Pharmacological and clinical profile of telmisartan, a selective angiotensin II type-1 receptor blocker

Folia Pharmacologica Japonica

Volumn 124, Issue 1, 2004, Pages 31-39

  Chachin, Motohiko ^a   Ohmura, Tsuyoshi ^a   Hayashi, Naoyuki ^b   Nishimura, Yoichiro ^b   Satoh, Hisashi ^a  

^a NIPPON BOEHRINGER INGELHEIM CO LTD   (Japan)

^b Medical Development Division   (Japan)

Author keywords

Angiotensin II receptor blocker; Antihypertensive agent; Hypertension; Morning surge; Telmisartan

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LONG ACTING DRUG; TELMISARTAN;

ARTERY CONSTRICTION; BINDING AFFINITY; BINDING ASSAY; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; DISEASE SEVERITY; DISSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TOLERANCE; ESSENTIAL HYPERTENSION; EXPERIMENTAL MODEL; HUMAN; ISOLATED ARTERY; NONHUMAN; OUTCOMES RESEARCH; RAT STRAIN; REBOUND; REVIEW; VASCULAR RING;

ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BENZOATES; HUMANS; MALE; RATS; RECEPTOR, ANGIOTENSIN, TYPE 2;

EID: 3242798311     PISSN: 00155691     EISSN: None     Source Type: Journal    
DOI: 10.1254/fpj.124.31     Document Type: Review

References (50)

1. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001; 358:1033-1041.
2. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-153.
3. Flather MD, Yusuf S, Kober L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet. 2000;355:1575-1581.
4. Morice AH, Lowry R, Brown MJ, Higenbottam T. Angiotensin-converting enzyme and the cough reflex. Lancet. 1987;2:1116-1118.
5. Padmanabhan N, Jardine AG, McGrath JC, Connell JM. Angiotensin-converting enzyme-independent contraction to angiotensin I in human resistance arteries. Circulation. 1999;99:2914-2920.
6. Urata H, Kinoshita A, Misono KS, Bumpus FM, Husain A. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem. 1990;265:22348-22357.
7. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355:1582-1587.
8. Cohn JN, Tognoni G. Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667-1675.
9. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003.
10. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870-878.
11. Jpn Circt J. 2000:64 Suppl V.
12. Goldberg RJ, Brady P, Muller JE, et al. Time of onset of symptoms of acute myocardial infarction. Am J Cardiol. 1990;66:140-144.
13. Willich SN, Lowel H, Lewis M, et al. Association of wake time and the onset of myocardial infarction. Triggers and mechanisms of myocardial infarction (TRIMM) pilot study. TRIMM Study Group. Circulation. 1991;84 Suppl 6:VI62-VI67.
14. Marler JR, Price TR, Clark GL, et al. Morning increase in onset of ischemic stroke. Stroke. 1989;20: 473-476.
15. Smolensky MH, D'Alonzo GE. Biologic rhythms and medicine. Am J Med. 1988;85:34-46.
16. Muller JE, Tofler GH, Stone PH. Circadian variation and triggers of onset of acute cardiovascular disease. Circulation. 1989;79:733-743.
17. Rocco MB, Barry J, Campbell S, et al. Circadian variation of transient myocardial ischemia in patients with coronary artery disease. Circulation. 1987;75:395-400.
18. Entzeroth M, Hadamovsky S. Angiotensin II receptors in the rat lung are of the AII-1 subtype. Eur J Pharmacol. 1991;206:237-241.
19. Wienen W, Entzeroth M. Effects on binding characteristics and renal function of the novel, nonpeptide angiotensin II antagonist BIBR277 in the rat. J Hypertens. 1994;12:119-128.
20. Wienen W, Hauel N, Van Meel JCA, Narr B, Ries U, Entzeroth M. Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277. Br J Pharmacol. 1993;110:245-252.
21. Vauquelin G, Van Liefde I, Birzbier BB, Vanderheyden PML. New insights in insurmount-able antagonism. Fundam Clin Pharmacol. 2002;16: 263-272.
22. st International Symposium on Angiotensin II Angionism. 1997; Abstract P15.
23. Wienen W, Entzeroth M, van Meel JCA van, et al. A review on telmisartan: a novel, long-acting angiotensin II-receptor antagonist. Cardiovasc Drug Rev. 2000;18:127-156.
24. 1) receptor antagonist, in conscious monkeys. FASEB J. 1994;8:A882, Abstract 5113.
25. Wienen W, Schierok HJ. Effects of telmisartan, hydrochlorothiazide and their combination on blood pressure and renal excretory parameters in spontaneously hypertensive rats. J Renin Angiotensin Aldosterone Syst. 2001;2:123-128.
26. Wagner J, Drab M, Bohlender J, Amann K, Wienen W, Ganten D. Effects of AT1 receptor blockade on blood pressure and the renin-angiotensin system in spontaneously hypertensive rats of the stroke prone strain. Clin Exp Hypertens. 1998;20:205-221.
27. Boehm M, Lee M, Kreutz R, et al. Angiotensin II receptor blockade in TGR(mREN2)27: effects of renin-angiotensin-system gene expression and cardiovascular functions. J Hypertens. 1995;13:891-899.
28. Sukenaga Y, Kamoshita K, Takai S, Miyazaki M. Development of the chymase inhibitor as an anti-tissue-remodeling drug: myocardial infarction and some other possibilities. Jpn J Pharmacol. 2002;90: 218-222.
29. Takai S, Miyazaki M. Effect of chymase inhibitor on vascular proliferation. Jpn J Pharmacol. 2002; 90:223-227.
30. Wienen W, Richard S, Champeroux P, Audeval-Gerard C. Comparative antihypertensive and reno-protective effects of telmisartan and lisinopril after long-term treatment in hypertensive diabetic rats. J Renin Angiotensin Aldosterone Syst. 2001;2:31-36.
31. Izumi H, Nakai T, Kano S, Hoshi K, Ichihara K. Effects of BIBR-277, an angiotensin II type 1 receptor antagonist, on stunned myocardium in dogs. Coron Artery Dis. 1996;7:775-779.
32. Stangier J, Su CA, Roth W. Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients. J Int Med Res. 2000;28:149-167.
33. Schmid J, Beschke K, Ebner T, Busch U, Prox A, Wachsmut H. In vivo and in vitro biotransformation of telmisartan. 1st Int Symp on Angiotensin II Antagonism. London: 1997. p. 13.
34. Ebner T, Roth W. In vitro glucuronidation of telmisartan, a novel angiotensin II receptor antagonist. 2nd Int Symp on Angiotensin II Antagonism. London: 1999. p. 44
35. 14C]telmisartan in healthy volunteers. J Clin Pharmacol. 2000;40:1312-1322.
36. 1) receptor blockers in hypertension. J Hum Hypertens. 2000;14 Suppl 1:S73-S86.
37. Stangier J, Su CA, Schondorfer G, Roth W. Pharmacokinetics and safety of intravenous and oral telmisartan 20 mg and 120 mg in subjects with hepatic impairment compared with healthy volunteers. J Clin Pharmacol. 2000;40:1355-1364.
38. 1 receptor antagonist telmisartan in patients with mild to moderate hypertension. Adv Ther. 1998;15:206-217.
39. Flesch G, Muller P, Lloyd P. Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man. Eur J Clin Pharmacol. 1997;52:115-120.
40. 14C-candesartan cilexetil in healthy volunteers. J Hum Hypertens. 1997;11 Suppl 2:S27-S28.
41. Lo MW, Goldberg MR, McCrea JB, Lu H, Furtek CI, Bjornsson TD. Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clin Pharmacol Ther. 1995;58:641-649.
42. Smith DH, Matzek KM, Kempthorne-Rawson J. Dose response and safety of telmisartan in patients with mild to moderate hypertension. J Clin Pharmacol. 2000;40:1380-1390.
43. Mallion J, Siche J, Lacourciere Y. ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension. J Hum Hypertens. 1999;13:657-664.
44. Lacourciere Y, Lenis J, Orchard R, et al. A comparison of the efficacies and duration of action of the angiotensin II receptor blockers telmisartan and amlodipine. Blood Press Monit. 1998;3:295-302.
45. Unger T. The ongoing telmisartan alone and in combination with ramipril global endpoint trial program. Am J Cardiol. 2003;91:28G-34G.
46. Weber M. The telmisartan Programme of Research tO show Telmisartan End-organ proteCTION (PROTECTION) programme. J Hypertens. 2003;21 Suppl 6:S37-S46.